Pharma major Dr Reddy's Laboratories on Monday said it has launched generic lipid-regulating tablets in the US market.
The company's Fenofibrate tablets USP in the strengths of 54 mg and 160 mg are approved by the US Food and Drug Administration (USFDA), Dr Reddy's said in a filing to BSE.
The product is a generic version of AbbVie Inc's Tricor tablets, it added.
According to IQVIA Health data, the Tricor brand and generic had US sales of around USD 90 million moving annual total (MAT) for the most recent 12 months ending in January 2020, Dr Reddy's said.
The company's tablets are available in 54 mg dose in bottle count size of 90, and 160 mg dose in bottle count sizes of 90 and 500, it added.
Shares of Dr Reddy's Laboratories were trading at Rs 3,991 per scrip on BSE, down 0.28 per cent from their previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app